Particella

Executive Summary

Particella is a preclinical-stage biotechnology company pioneering an oral lipid nanoparticle (LNP) platform for the delivery of nucleic acids, including mRNA, specifically to the intestinal epithelium. Founded in 2021 and based in San Francisco, the company aims to transform the treatment of gastrointestinal and systemic diseases by enabling patient-friendly oral administration of genetic medicines, eliminating the need for injections. Their proprietary LNP technology is designed to withstand the harsh gastrointestinal environment and achieve targeted uptake by intestinal cells, potentially unlocking new therapeutic possibilities for conditions such as inflammatory bowel disease, metabolic disorders, and vaccine applications. As a preclinical entity, Particella is focused on advancing its platform through proof-of-concept studies and IND-enabling activities. The company represents an early-stage opportunity in the rapidly evolving field of oral mRNA delivery, which holds significant promise for improving patient compliance and expanding the addressable market for nucleic acid therapeutics. While the platform is still in development and faces technical challenges related to stability and bioavailability, its differentiation from injectable counterparts could position it as a valuable asset in the biotech landscape. Success will depend on robust preclinical data and strategic partnerships to support further development and clinical translation.

Upcoming Catalysts (preview)

• Q3 2026Presentation of in vivo proof-of-concept data for oral mRNA delivery at a major conference60% success
• Q4 2026Completion of Series A financing round to fund IND-enabling studies70% success
• Q1 2027Initiation of GLP toxicology studies for lead candidate50% success